Objective:
To summarize the FDA approval of cemdisiran for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, the supporting NIMBLE trial findings, and key prescribing information.
Approach:
- Treatment: Cemdisiran (Livsayis) is a subcutaneous siRNA that targets messenger RNA encoding complement component 5 (C5), reducing C5 production. The recommended dose is 567 mg every 3 months, administered by a health care provider.
- Evidence: Approval was supported by the phase 3 NIMBLE randomized, double-blind, placebo-controlled trial of 284 patients. The primary endpoint was change in MG-ADL score from baseline to week 24.
Key Findings:
- In the primary analysis population of 123 patients, MG-ADL improved by 4.5 points with cemdisiran and 2.2 points with placebo; the placebo-adjusted difference was 2.3 points.
- At least a 3-point MG-ADL improvement occurred in 76.6% of cemdisiran recipients and 44.1% of placebo recipients.
- QMG scores improved by 4.2 points with cemdisiran and 1.5 points with placebo, a placebo-adjusted improvement of 2.8 points. At least a 5-point improvement occurred in 48.4% and 19%, respectively.
- The prescribing information carries a boxed warning for serious meningococcal infections and requires use through a restricted Risk Evaluation and Mitigation Strategy program.
Interpretation:
The FDA approved cemdisiran as the first siRNA therapy for gMG and the only FDA-approved gMG treatment with quarterly subcutaneous dosing, according to Regeneron.
Limitations:
- The primary analysis population included 123 patients, although the trial enrolled 284.
- The provided context does not report trial results beyond week 24.
Conclusion:
Cemdisiran is administered at 567 mg subcutaneously every 3 months by a health care provider. The label requires meningococcal vaccination at least 2 weeks before treatment; patients needing urgent treatment who are not up to date with vaccination should receive antibacterial prophylaxis. Treatment must not be initiated in patients with an unresolved serious Neisseria meningitidis infection. The label also warns about other serious infections associated with reduced complement activity. Reported adverse reactions with cemdisiran versus placebo included injection-site reactions (8% vs 3%), viral infections (6% vs 4%), and urinary tract infections (5% vs 4%).
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
